[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sibo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sibo":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,77,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629789","breath-test-based-assessment-of-sibo-in-chronic-pancreatitis-and-partial-pancreatectomy-100629789",false,"NCT07479238","Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy","Prevalence of SIBO in Patients With Chronic Pancreatitis and After Partial Pancreatectomy: Assessment by Glucose, Lactulose and Mixed Triglyceride Breath Tests.","DCP-PCT-EPI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability and willingness to participate in the study and to comply with study procedures\n* Diagnosis of chronic pancreatitis with pancreatic exocrine insufficiency (defined as fecal elastase \\\u003C 200 µg\u002Fg of stool)\n* Ongoing pancreatic enzyme replacement therapy (PERT) with persistent gastrointestinal symptoms (including abdominal pain, dyspepsia, bloating, excessive flatulence, diarrhea, or steatorrhea) or unintentional weight loss ≥ 10% within the previous 6 months despite adequate PERT dosing (≥ 40,000 IU per main meal and half dose for snacks)\n* Patients with ampullary or pancreatic tumors who underwent partial pancreatectomy and subsequently developed pancreatic exocrine insufficiency with persistent gastrointestinal symptoms\n* Indication to undergo glucose, lactulose, and mixed triglyceride breath tests as part of routine clinical practice\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or \\> 75 years\n* Pancreatic adenocarcinoma or bile duct tumors under active or previous adjuvant therapy\n* Moderate to severe liver disease\n* Severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* History of major gastrointestinal surgery, including total pancreatectomy\n* Presence of other active organic gastrointestinal diseases\n* Diabetic gastroparesis\n* Known celiac disease\n* Obstructive jaundice\n* Liver cirrhosis Child-Pugh class C\n* Recent or ongoing infections\n* Severe chronic obstructive pulmonary disease (COPD)\n* Symptomatic thyroid disorders\n* Use of antibiotics, laxatives, probiotics, or prokinetic agents within 4 weeks prior to breath testing\n* Inability or refusal to undergo study procedures\n* Inability or refusal to provide informed consent","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life. Although pancreatic enzyme replacement therapy (PERT) is the standard treatment, some patients remain symptomatic despite apparently adequate therapy. Possible causes include suboptimal dosing or concomitant conditions such as small intestinal bacterial overgrowth (SIBO). This study aims to determine the prevalence of SIBO in symptomatic PEI patients despite adequate PERT and to identify treatable causes of persistent symptoms using non-invasive diagnostic tests, with the goal of improving nutritional status and quality of life.",[26,27,28,29],"SIBO","Pancreatic Insufficiency","Chronic Pancreatitis","Pancreatic Surgey",[31,32,33,34],"Pancreatic exocrine insufficiency","Chronic pancreatitis","enzyme replacement therapy","Small intestinal bacterial overgrowth","NOT_YET_RECRUITING","2026-04-09",{"date":38,"type":39},"2026-04-13","ACTUAL",{"date":41,"type":22},"2026-04-30",{"date":43,"type":22},"2028-04-26",{"name":45,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100394607","capillary-endoscopy-aspiration-catheter-100394607","NCT04418258","Capillary Endoscopy Aspiration Catheter","Evaluation of a Capillary Endoscopy Aspiration Catheter","Inclusion Criteria:\n\n* Male or female subjects aged 18-85 undergoing esophagogastroduodenoscopy.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study as subjects will be undergoing the procedures for medical reasons and not for the purposes of this study.","85 Years",{"count":57,"type":22},46,"INTERVENTIONAL",[60],"NA","The small intestine is an understudied frontier of microbiome research. While aspiration during endoscopy is considered the gold standard to assess small bowel bacteria, the tools for sterile retrieval are primitive and poorly validated.\n\nEndoscopic aspiration is time-consuming and prone to contamination. Inspired by plants' ability to draw water by capillary action, a novel multi-capillary sterile system was designed which is a modified version of the conventional aspiration catheter.\n\nThe purpose of this study is to examine the time and volume capabilities of this catheter in suctioning various liquids compared to conventional aspiration catheter, in two groups, each includes 23 patients that going under endoscopy at GI lab at Cedars Sinai Medical Center. The investigator will collect up to 2 ml fluid from Duodenum- in first group by using the conventional catheter and in second group by using the capillary catheter. The time collection and the volume of samples in 2 groups will be compared.",[63,26],"Microbiota",[65,26,66],"Endoscopy aspiration Catheter","Gut Microbiome","RECRUITING","2026-01-23",{"date":70,"type":39},"2026-01-26",{"date":72,"type":39},"2020-05-20",{"date":74,"type":22},"2027-06-01",{"name":76,"class":46},"Cedars-Sinai Medical Center",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":58,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100575421","efficacy-of-rifaximin-in-patients-with-small-intestinal-bacterial-overgrowth-presenting-with-abdominal-bloating-100575421","NCT06772064","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating: An Exploratory Study.","Healthy Group\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. No special gastrointestinal discomfort such as bloating or abdominal pain, regular bowel movements, and normal stool characteristics.\n3. Negative hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.\n\nPatient Group:\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. Chief complaints of abdominal bloating and\u002For distension; outpatients with abdominal bloating and\u002For distension more prominent than other symptoms.\n3. Positive hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Moderate to severe abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.",true,"70 Years",{"count":87,"type":22},115,[60],"Abdominal bloating is a common clinical symptom in the digestive system, with obscure origins and complex mechanisms. Its etiology can be attributed to organic diseases and various Functional Gastrointestinal Disorders (FGIDs). In recent years, the roles of Small Intestinal Bacterial Overgrowth (SIBO), Oral-Cecal Transit Time (OCTT), and gut microbiota dysbiosis in Functional Abdominal Bloating\u002FDistention (FAB\u002FD) have garnered increasing attention. Currently, there is a lack of diagnostic tests and effective treatment measures for patients with bloating. The hydrogen\u002Fmethane breath test is a safe, economical, and non-invasive examination recommended for diagnosing SIBO. Rifaximin, an antibiotic that acts exclusively in the intestines, has been widely validated for its efficacy in SIBO and in patients with SIBO co-occurring with Irritable Bowel Syndrome (IBS). However, research on the role of SIBO in the production of bloating symptoms and the extent to which rifaximin treatment of SIBO alleviates symptoms in clinical bloating patients is still lacking. This study aims to investigate the efficacy of rifaximin in patients with SIBO who primarily present with bloating. Exploring clinical treatment options for bloating provides a reference for its management. Furthermore, questionnaires on psychiatric symptoms and fecal microbiota analysis for patients with bloating-type SIBO can help clarify the etiology of bloating, offering a basis for the etiological treatment of bloating patients in the next steps.",[26],[26,92,93],"Abdominal bloating","Rifaximin","2025-05-13",{"date":96,"type":39},"2025-05-16",{"date":98,"type":39},"2025-04-15",{"date":100,"type":22},"2025-12-01",{"name":102,"class":46},"Xiuli Zuo",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100540484","the-safety-and-efficacy-of-a-probiotic-intervention-on-lactulose-hydrogen-breath-test-positive-patients-and-related-gastrointestinal-symptoms-100540484","NCT06317441","The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms","Inclusion Criteria:\n\n1. Aged 18-65 years old at the inclusion of the study, both female and male subjects.\n2. Signed Informed Consent; willing and able to comply with study procedures.\n3. Willing to maintain their diet and physical activity levels during the study.\n4. Able to swallow a size-00 capsule (23mm length and 9mm width).\n5. Participants with at least one of the following Rome IV diagnoses: FABD, functional diarrhea, IBS-M, or IBS-D.\n6. Baseline weekly average of worst daily (in past 24 hours) abdominal bloating\u002Fdistension score of \\>= 3.0 on a 0-to-10-point scale.\n7. Participants with abnormal LHBT following the North American Consensus recommendations (A rise in hydrogen of ≥20 ppm by 90 min).\n\nExclusion Criteria:\n\n1. History of less than three (3) bowel movements per week.\n2. With the diagnosis of IBS-C.\n3. Prior gastrointestinal disease, surgery, or abdominal or pelvic radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, any IBD, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.\n4. Persons with central venous catheters.\n5. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction.\n6. Known history abdominal radiation treatment.\n7. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, or GLP-1 analogues); laxative use is allowed if used less than 3 times a week and it is willing to keep unchanged in the week prior to the SIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a wash-out period of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.\n\n   o Prokinetic use. Potential participants who are not using prokinetics to treat SIBO may be eligible after a 2-week washout period, and willing to not use prokinetics for the study duration.\n8. Unable to stop using laxatives or prokinetic medications for 4 days before the study procedure (BT). Laxatives can be resumed after the test is conducted.\n9. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.\n10. Celiac disease (treated or untreated).\n11. Any significant heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome.\n12. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable).\n13. Gastrointestinal inflammatory diseases, including ulcerative colitis, Crohn's disease, microscopic colitis.\n14. Participants with IBS presenting with alarm symptoms such as: rectal bleeding, unexplained weight loss, iron deficiency anemia, and nocturnal symptoms,\n15. Participants over the age of 50 or older who have not had:\n\n    * a colon cancer screening by either a negative FIT or FOBT test within the last 2 years; OR\n    * a colonoscopy in the prior 10 years which was negative for colorectal cancer\n16. Epilepsy diagnosis.\n17. History or diagnosis of immunological diseases, infectious diseases or immune-compromised conditions, which in the opinion of the investigator, would adversely affect study safety or outcome. Such as, but not limited to, hepatitis, tuberculosis, HIV positive, Parkinson's, multiple sclerosis, AIDS, lymphoma, and long-term corticosteroid treatment.\n18. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.\n19. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.\n20. Regular use of probiotics, prebiotics or synbiotics (including food and drinks containing added probiotics and\u002For probiotic yogurts with live, active cultures) within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.\n21. Any prior Fecal Microbiota Transplantation.\n22. Pregnant or breastfeeding.\n23. Planning to become pregnant.\n24. Alcohol or drug abuse.\n25. Allergy to the components present in the probiotic and placebo capsules.\n26. Are non-English speaking.\n27. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed.","65 Years",{"count":111,"type":22},105,[60],"The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.",[115,26],"Small Intestinal Bacterial Overgrowth",[117,118,119,120,121,122,123,124,125,126],"Functional abdominal bloating and distension","Functional Diarrhea","Irritable Bowel Syndrome with Diarrhea","Irritable Bowel Syndrome","Abdominal Bloating","IBS","IBS-D","FABD","Functional Gastrointestinal Disorders","FGID","2025-04-24",{"date":129,"type":39},"2025-04-29",{"date":131,"type":39},"2024-07-20",{"date":133,"type":22},"2026-12",{"name":135,"class":136},"Nimble Science Ltd.","INDUSTRY"]